Braasch Biotech announced that they have received the first patent for anti-somatostatin vaccine for the treatment of obesity in dogs and cats. This is the first patent granted for the treatment of obesity by the vaccine.
Happily curious prevalence of obesity among farmers move in parallel with their pets. In the U.S., 52.5% of dogs and 58.3% of the cats are overweight. U.S. veterinarians warn that 80 million dogs at risk of arthritis, diabetes, hypertension and a number of cancers.
Just like in humans, obesity in pets reached epidemic dimensions. Once reached the pathological condition, the animal needs the intervention of the holder in order to revert to a healthy weight. The vaccine is one of the few alternatives other than additional walks in the park. Yet its registration in the European Union, Brazil, Mexico, Canada, the USA and Japan.
Braasch Biotech have an extensive portfolio of anti-somatostatin products for the treatment of a number of metabolic diseases.